$28.96
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment
Overview
52-week range
$11
$40
62% of range
Avg surprise (last 3)
+214.9%
Avg reaction (last 2)
-4.5%
0% positive
Latest IV / EM
86%
EM ±19.7% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.79 | $-0.80 | +1.2% | -141.6% | -1.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.65 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.40 | $-0.57 | +29.8% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $1.90 | $-0.37 | +613.5% | — | -7.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.47 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.46 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.57 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.55 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.69 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.82 | -$0.40 | -105.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | — | $11M | $14M | $159M | — | $5M | $5M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-53M | — | $-43M | $-27M | $111M | — | $-30M | $-29M |
| Net income | $-50M | — | $-38M | $-23M | $113M | — | $-26M | $-26M |
| EPS (diluted) | $-0.79 | — | $-0.65 | $-0.40 | $1.90 | — | $-0.47 | $-0.46 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $156M | $84M | $83M | $101M | $275M | $128M | $150M | $193M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $367M | $306M | $272M | $270M | $376M | $233M | $254M | $297M |
| Total assets | $443M | $418M | $360M | $385M | $407M | $272M | $293M | $308M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $48M | $66M | $52M | $50M | $57M | $43M | $61M | $65M |
| Total equity | $395M | $352M | $308M | $335M | $350M | $229M | $232M | $243M |